43083-12-1 Usage
Description
Trimethyl orthobutyrate is an organic compound that serves as an acetylating agent in various chemical reactions and processes.
Uses
Trimethyl orthobutyrate is used as an acetylating agent for the preparation of:
1. 5-acetamido-9-O-butyroyl-3,5-dideoxy-D-glycero-2-nonulo pyranosonic acid
2. 9-O-butyroyl-3,5-dideoxy-5-glycoloylamido-D-glycero-2-nonulo pyranosonic acid
Trimethyl orthobutyrate is also used for:
1. Acylation at OH-9 of N-acetylneuraminic acid and N-glycoloylneuraminic acid to give the corresponding 9-O-acylated derivatives.
2. Conversion of 2-amino-N-(1-H-benzimidazol-2-yl)benzamide to 2-propyl-3-benzimidazolyl-4(3H)-quinazolinone.
3. Preparation of 2-propyl substituted benzimidazoles from 1,2-benzenediamines.
Additionally, Trimethyl orthobutyrate can be used in the total synthesis of:
1. dl-camptothecin
2. Olmesartan Medoxomil
3. DE and CDE ring analogs of camptothecin
4. Homologs of 1,25-dihydroxyvitamin D3.
Check Digit Verification of cas no
The CAS Registry Mumber 43083-12-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,3,0,8 and 3 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 43083-12:
(7*4)+(6*3)+(5*0)+(4*8)+(3*3)+(2*1)+(1*2)=91
91 % 10 = 1
So 43083-12-1 is a valid CAS Registry Number.
InChI:InChI=1/C7H16O3/c1-5-6-7(8-2,9-3)10-4/h5-6H2,1-4H3
43083-12-1Relevant articles and documents
Process for preparation of adjacently disubstituted ketones
-
, (2008/06/13)
A novel 7-hydroxyprostaglandin E1, or a stereoisomer thereof, or a protected derivative thereof, having the following formula: STR1 wherein R8 represents H, CH3 or C2 H5, R9 represents H or CH3, R10 and R11 are identical or different, and each represents H, tetrahydropyranyl or t-butyldimethylsilyl. Also provided is a process for producing an adjacently disubstituted ketone including the above compounds, i.e. 7-oxoprostaglandin, etc. which comprises reacting an α,β-unsaturated carbonyl compound with a cuprous salt and an organolithium compound in an aprotic inert organic medium in the presence of trialkylphosphine, the amounts of said cuprous salt and said organolithium compound being substantially equimolar, and reacting the product with a protected acetal derivative of an organic carbonyl compound or an aldehyde in the presence of a Lewis acid, if necessary, followed by reacting the product with a proton donor.